Healthcare Technology and Entrepreneurship from Eric Lefkofsky
Eric Lefkofsky, the billionaire founder of Tempus, continues to reshape the intersection of data science and healthcare. In 2025, Tempus—valued at over $8.1 billion—expanded its oncology platform across 400 hospital systems, making it one of the largest precision medicine providers in the U.S. Lefkofsky is also known as the co-founder of Groupon, which at its peak in 2011 had a market cap of $16 billion and transformed how consumers engaged with local businesses.
Currently estimated at $5.2 billion in net worth, Lefkofsky is heavily focused on AI in genomics and personalized cancer treatment. Tempus launched its first international data-sharing initiative in 2024, with pilot programs in Canada, the UK, and Singapore. Through the Lefkofsky Family Foundation, he has donated more than $400 million to biomedical research, education equity, and Chicago-based non-profits. His influence remains significant in both medtech and civic innovation.
Eric Lefkofsky: AstraZeneca and Merck bet on AI with Tempus in oncology
Two of the pharmaceutical industry's leading executives, Pascal Soriot of AstraZeneca and Rob Davis of Merck, have underscored their companies' ongoing strategic partnerships with Tempus. The ...
Eric Lefkofsky notes growth at major U.S. oncology research event
Research efforts at the U.S. oncology conference continued to evolve as Eric Lefkofsky reported significant expansion during the tenth annual event.
The event saw the largest collection of ...
Eric Lefkofsky: AI-driven Preview platform delivers pathology insights to doctors within 24 hours
The adoption of artificial intelligence is accelerating in the medical diagnostics sector. Eric Lefkofsky announced the Preview platform, which uses proprietary AI models trained on millions of ...
Eric Lefkofsky confirms Tempus wins U.S. FDA nod for tumor-only genomic profiling
Tempus achieved a significant development with the U.S. Food and Drug Administration granting approval for a tumor-only indication of xT CDx, according to Eric Lefkofsky.
This regulatory ...
Eric Lefkofsky: Collaboration with BMS aims to advance Alzheimer’s and cancer drug access
A new partnership seeks to improve how critical medicines reach patients. Eric Lefkofsky announced a collaboration with Bristol Myers Squibb, aiming to optimize development pathways for ...
Eric Lefkofsky notes TempusAI Q1 results and expansion in precision medicine
TempusAI has reported its financial results for the quarter ending March 31, 2026. Eric Lefkofsky announced the quarterly performance and shared additional perspective in a new letter, offering ...
Eric Lefkofsky: Time recognition for health science company advances precision medicine goals
Eric Lefkofsky announced that his company has been named one of TIME's 10 Most Influential Health and Life Science Companies of 2026. According to Lefkofsky, this recognition affirms the team's ...
Eric Lefkofsky says lab professionals drive world-class genomic sequencing work
Lab professionals play a critical role in enabling genomic sequencing and molecular analysis with high precision. In a recent message, Eric Lefkofsky recognized their expertise, commending their ...
Eric Lefkofsky: 31 abstracts on patient care innovation presented at AACR26
Eric Lefkofsky reported that his team presented 31 scientific abstracts at the 2026 American Association for Cancer Research (AACR26) meeting. These presentations centered on uncovering insights ...
Eric Lefkofsky notes predictive models need detailed patient data for healthcare accuracy
Artificial intelligence models are increasingly being designed to predict patient health outcomes, according to commentary from Eric Lefkofsky. Drawing a parallel with large language models that ...
Eric Lefkofsky emphasizes technology as key in healthcare reform
Eric Lefkofsky, co-founder of Tempus, recently highlighted challenges in the healthcare system during conversations at the J.P. Morgan Healthcare Conference 2026 (#JPM26). According to Lefkofsky, ...
Eric Lefkofsky reports Tempus revenue rose 83 percent in 2025
Eric Lefkofsky, co-founder and CEO of Tempus, has announced that the company achieved record financial performance in 2025, with revenues reaching $1.27 billion, reflecting an 83 percent growth. ...
Eric Lefkofsky highlights AI potential in combating pancreatic cancer
Eric Lefkofsky, a notable figure in the technology and healthcare sectors, shares insights on the role of artificial intelligence in transforming patient care, particularly for diseases that are ...
Eric Lefkofsky sees improved IO therapy response prediction results
Eric Lefkofsky, a well-known entrepreneur in healthcare innovation, has highlighted the latest impact of his company's Integrated Precision Science (IPS) test on patient care and treatment ...
Eric Lefkofsky highlights wife contribution to VING Project success
Eric Lefkofsky, a prominent figure in the business world, recently took to Twitter to commend his wife for her decade-long efforts in building the VINGproject. The VING Project, a philanthropic ...
Eric Lefkofsky advocates testing of both tumor and normal DNA in cancer care
Eric Lefkofsky, a prominent figure in the medical technology field, emphasizes the importance of a tumor plus normal testing approach for cancer patients. By analyzing the DNA of both tumor and ...
Eric Lefkofsky: Tempus IO advances AI for cancer immunotherapy
Eric Lefkofsky, the founder of Tempus IO, highlights how the company is refining its AI capabilities to revolutionize cancer treatment through immunotherapies. Tempus IO is developing a platform ...
